Merck and Co Inc   (MRK)
Other Ticker:  
Price: $111.0700 $-1.23 -1.095%
Day's High: $113.19 Week Perf: -2.99 %
Day's Low: $ 110.65 30 Day Perf: -3.55 %
Volume (M): 6,378 52 Wk High: $ 119.65
Volume (M$): $ 708,438 52 Wk Avg: $101.16
Open: $112.00 52 Wk Low: $83.05

 Market Capitalization (Millions $) 282,421
 Shares Outstanding (Millions) 2,543
 Employees 68,000
 Revenues (TTM) (Millions $) 59,283
 Net Income (TTM) (Millions $) 14,526
 Cash Flow (TTM) (Millions $) 4,606
 Capital Exp. (TTM) (Millions $) 4,388

Merck And Co Inc
Merck & Co., Inc.,'is a global research-driven pharmaceutical products company that discovers, develops, manufactures and markets a broad range of innovative products to improve human and animal health, directly and through its joint ventures. The Company sells its products primarily to drug wholesalers and retailers, hospitals, clinics, government agencies and managed health care providers such as health maintenance organizations and other institutions. The Company's professional representatives communicate the effectiveness, safety and value of its products to health care professionals in private practice, group practices and managed care organizations.

The Company's products include therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. Among these are atherosclerosis products, of which Zocor (simvastatin)'is the largest-selling; hypertension/heart failure products, the most significant of which are Cozaar (losartan potassium), Hyzaar (losartan potassium and hydrochlorothiazide), and Vasotec (enalapril maleate); anti-inflammatory/analgesics, which include Vioxx (rofecoxib)'and Arcoxia (etoricoxib), agents that specifically inhibit the COX-2 enzyme, which is responsible for pain and inflammation ('coxibs'); an osteoporosis product, Fosamax (alendronate sodium), for treatment and prevention of osteoporosis; a respiratory product, Singulair (montelukast sodium), a leukotriene receptor antagonist for treatment of asthma and for relief of symptoms of seasonal allergic rhinitis; vaccines/biologicals, of which M-M-R II (measles, mumps and rubella virus vaccine live), Varivax (varicella virus vaccine live), a live virus vaccine for the prevention of chickenpox, and Recombivax HB (hepatitis B vaccine [recombinant]) are the largest-selling; anti-bacterial/anti-fungal products, which includes Primaxin (imipenem and cilastatin sodium), as well as newer products Cancidas (caspofungin acetate) and Invanz (ertapenem sodium); ophthalmologicals, of which Cosopt (dorzolamide hydrochloride and timolol maleate ophthalmic solution) and Trusopt (dorzolamide hydrochloride ophthalmic solution) are the largest-selling; a urology product, Proscar (finasteride), for treatment of symptomatic benign prostate enlargement; and HIV products, which include Crixivan (indinavir sulfate) and Stocrin (efavirenz), for the treatment of human immunodeficiency viral infection in adults.

Other primarily includes Maxalt (rizatriptan benzoate), for the treatment of acute migraine headaches in adults, Propecia (finasteride), for the treatment of male pattern hair loss, and other non-promoted products and pharmaceutical and animal health supply sales to the Company's joint ventures and revenue from the Company's relationship with AstraZeneca LP, primarily relating to sales of Nexium (esomeprazole magnesium) and Prilosec (omeprazole).

Our business is preserving and improving human life and animal health. All of our actions must be measured by our success in achieving this goal. Above all, we value our ability to serve patients who can benefit from the appropriate use of our products and services. We are dedicated to providing the highest level of professional excellence and health delivery systems. We strive to identify the most critical needs of health care professionals and consumers, and we devote our resources to meeting those needs.

Competition ' The markets in which the Company's pharmaceutical business is conducted are highly competitive and often highly regulated. Global efforts toward health care cost containment continue to exert pressure on product pricing and access.

Such competition involves an intensive search for technological innovations and the ability to market these innovations effectively. With its long-standing emphasis on research and development, the Company is well prepared to compete in the search for technological innovations. Additional resources to meet competition include quality control, flexibility to meet customer specifications, an efficient distribution system and a strong technical information service. The Company is active in acquiring and marketing products through joint ventures and licenses and has been refining its sales and marketing efforts to further address changing industry conditions. To enhance its product portfolio, the Company continues to pursue external alliances, from early-stage to late-stage product opportunities, including joint ventures and targeted acquisitions. However, the introduction of new products and processes by competitors may result in price reductions and product replacements, even for products protected by patents. For example, the number of compounds available to treat diseases typically increases over time and has resulted in slowing the growth in sales of certain of the Company's products.

   Company Address: 126 East Lincoln Avenue Rahway 7065 NJ
   Company Phone Number: 740-4000   Stock Exchange / Ticker: NYSE MRK
   MRK is expected to report next financial results on August 03, 2023. Next quarterly dividend pay out on July 07, 2023.

Customers Net Income fell by MRK's Customers Net Profit Margin fell to

-11.15 %

3.13 %

• Customers Performance • Customers Expend. • Customers Efficiency • List of Customers


Stock Performances by Major Competitors

5 Days Decrease / Increase
ABBV   -5.2%    
ABT   -5.56%    
BMY   -3.07%    
JNJ   -2.87%    
LLY   -3.75%    
PFE        2.26% 
• View Complete Report

Q Biomed Inc

The company has Turned into Profitability at the Major Pharmaceutical Preparations company in the fourth quarter of 2022 earnings season

For the fourth quarter of 2022 earnings season Q Biomed Inc had turn a round to surplus by exhibiting earnings per share of $0.02 per share compare to $-0.08 a year before and earnings per share turned positive from $-0.03 per share from the prior financial reporting period. The revenue went down sharply by -88.053 % to $0.01 million from $0.10 million in the comparable financial reporting period a year before and sequentially Revenue Tumbled by -52.286 % from $0.03 million.

23andme Holding Co

Redemption of Diminishing Returns at ME amid the fourth quarter of 2023 earnings season

23andme Holding Co Posts Mixed Q4 Results, Despite Lower Demand
23andme Holding Co, the popular genetic testing company, has released its latest earnings report for Q4 2023. In a disappointing development for investors, the company's revenue was hit hard by lower demand, leading to a vanishing revenue and higher deficit.
While the earnings report may have been mixed, there was some positive news to report. The company announced that it had been able to decrease its loss per share to $-0.13 per share, which may be seen as an encouraging sign to some investors. However, revenue decreased by -8.137% to $92.38 million, signifying that the company still has some way to go in order to generate more growth.

Shuttle Pharmaceuticals Holdings Inc

Shuttle Pharmaceuticals Holdings Inc released operating deficit of $-1.54478 million, in the Mar 31 2023 report

As the earnings season for January to March 31, 2023, continues, many corporations have announced their respective results. The pharmaceutical industry, a significant player in the global market, has also been reporting their earnings. One company that has recently released its earnings report is Shuttle Pharmaceuticals Holdings Inc.
Shuttle Pharmaceuticals Holdings Inc (SHPH), a rising player in the industry, has issued an operating deficit of $-1.54478 million for the first quarter of the 2023 earnings season. While the shareholders anticipate additional revenue sources to evolve in the near future, they are less interested in the corporation's current accomplishment.
It is not surprising that the company realized a net loss of $-0.975 million, which has extended from $-0.078 million in the financial quarter ending March 31, 2022. The shareholders' expectations of additional revenue streams reflect the investors' desire to see solid growth and profitability in the long run.
However, it is essential to understand that the pharmaceutical industry is highly competitive, which means that many significant companies operate in this space. These companies tend to have diversified product portfolios, expansive distribution networks, and significant marketing budgets, which can help secure their market share and profitability.
It is noteworthy that Shuttle Pharmaceuticals Holdings Inc is a rising player in the pharmaceutical industry, which means that the company is still finding its feet in the market. The most crucial measure of the company's growth and profitability in the long run will stem from the successful development, approval, and commercialization of its pipeline products.

Bullfrog Ai Holdings Inc

Bullfrog Ai Holdings Inc reported operating deficit of $-1.190645 million, in the Mar 31 2023 report

Bullfrog AI Holdings Inc: An Overview
Bullfrog AI Holdings Inc is a pharmaceutical company that specializes in creating innovative drugs using artificial intelligence (AI) technology. The company was founded in 2019, with headquarters located in Toronto, Canada. Bullfrog AI Holdings Inc is focused on developing new drugs for diseases that have no known cure. The company's primary aim is to revolutionize the pharmaceutical industry with its cutting-edge technologies and creative solutions.
The company's technological capabilities come from its emphasis on AI, machine learning, and data analytics. Bullfrog AI Holdings Inc uses AI technology to analyze vast amounts of data to identify drug candidates that have a high likelihood of success in clinical trials. This approach enables the company to produce drugs that are more efficient and effective than traditional drugs.

Ocean Biomedical Inc

Between many entities, the OCEA disclosed as well the first quarter of 2023 performance

Ocean Biomedical Inc. is a major pharmaceutical preparations company that specializes in developing, manufacturing, and distributing drugs and medical devices. The company has been in operation for several years and has a strong track record within the industry. However, like many companies in the pharmaceutical sector, Ocean Biomedical operates within a highly competitive market, where constantly evolving regulatory environments, technological advancements, and shifting consumer demands can have a significant impact on the company's performance.
In the first quarter of 2023, Ocean Biomedical Inc. faced significant challenges. The company announced a shortfall of $-67.401 million, which was a significant drop from the $0.043 million net income reported in the same period the previous year. The unexpected adjustment in revenue during the January to March 31 2023 reporting cycle caught shareholders off guard. However, investors had been monitoring Ocean Biomedical's operational shortfall, which stood at $-5.223 million during the same period.


Merck And Co Inc's Segments
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
 Segment     of total Revenue
Merck Pharmaceutical
 Segment     of total Revenue
 Segment     of total Revenue
All Other
 Segment     of total Revenue
• View Complete Report
  Company Estimates  
  Revenue Outlook
Merck And Co Inc announced annual revenue outlook on

Earnings Outlook
Merck and Co Inc issued annual earnings guidance on

Geographic Revenue Dispersion
United States
Asia Pacific
Latin America


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2023 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071